Heidi Kempinski

Praeventix, Inc. is a biotechnology company founded by Dr. Douglas Pippin based on discoveries researched by Dr. Pippin and at Temple University. The company is based in Exton, PA, and was founded by Douglas Pippin. The company is initially focused on the development of pre-clinical candidate pra-523, a potential first-in-class neuromodulatory therapy for pruritus and other potential indications, including IBD. Praeventix is pursuing novel serotonergic therapeutics for inflammatory bowel disease (IBD) and cocaine use disorder (CUD). Douglas Pippin has been the CEO since incorporation.

Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL.

Tellus BioVentures LLC (Tellus BioVentures) is a venture capital firm founded in 2019 by Leon O. Moulder. The firm is headquartered in Miromar Lakes, Florida.

Praeventix, Inc. is a biotechnology company founded by Dr. Douglas Pippin based on discoveries researched by Dr. Pippin and at Temple University. The company is based in Exton, PA, and was founded by Douglas Pippin. The company is initially focused on the development of pre-clinical candidate pra-523, a potential first-in-class neuromodulatory therapy for pruritus and other potential indications, including IBD. Praeventix is pursuing novel serotonergic therapeutics for inflammatory bowel disease (IBD) and cocaine use disorder (CUD). Douglas Pippin has been the CEO since incorporation.

Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL.

Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL.

Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL.